

**VANCOUVER HOSPITAL & HEALTH SCIENCES CENTRE  
CSU PHARMACEUTICAL SCIENCES  
SPECIAL ACCESS DRUG DATA SHEET**

---

**DRUG NAME**

Rifampin Sodium

**ALTERNATE NAME**

Rifadine®, rifampicine

---

**MANUFACTURER**

sanofi aventis

---

**STRENGTH**

600 mg vial as powder for reconstitution

**DOSAGE FORM**

Injection

---

**INDICATIONS**

- In combination with other agents in treatment of tuberculosis and other mycobacterial diseases when oral route is not feasible
- 

**DOSAGE AND ADMINISTRATION**

- Dosage
    - o Tuberculosis and other mycobacterial disease:
      - Adults: 600 mg IV daily
      - Infants < 1 week of age: maximum 10 mg/kg/day
      - Infants old > 1 week and children: 10-20 mg/kg/day
    - o Dosage adjustment not required in renal failure or during peritoneal dialysis or hemodialysis
  
  - Reconstitution
    - o Reconstitute contents of vial with 10mL of the provided solution for reconstitution. Final concentration of 60mg/mL is stable for 24 hours at room temperature.
    - o Swirl vial gently until contents are completely dissolved
    - o Dilute each 600 mg in at least 250mL of compatible infusion solution and infuse over 3 hours
    - o Stability in normal saline = 24 hrs and in D5W = 4 hrs; store at room temperature. Dilution in other infusion solutions is not recommended.
    - o Alternatively, the appropriate dose may be added to 100 mL of compatible solution and infused over 30 minutes
    - o Store unconstituted powder at room temperature
- 

**KNOWN SIDE EFFECTS\***

- GI disturbances include: heartburn, epigastric distress, nausea, vomiting, anorexia, diarrhea
  - Headache, drowsiness, mental confusion, pains in muscles and joints have also occurred, especially during the first few weeks of therapy pain and swelling at injection site; thrombophlebitis after prolonged use
  - Abnormal liver function tests
- 

**SPECIAL PRECAUTIONS**

- Incompatible with 5% sodium bicarbonate solution
  - Incompatible with other drugs
  - Hepatitis and jaundice have been reported in patients with pre-existing liver disease, or those receiving concomitant hepatotoxic drugs
  - High intermittent doses may cause shortness of breath, wheezing, hypotension and shock
  - If local irritation and inflammation due to extravascular infiltration of the infusion, discontinue the infusion and restart at another site
  - Do not administer by IM or SC routes
- 

**\* REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**